Climb Bio Inc. has announced an upcoming webcast event to highlight its CLYM116 program, scheduled for September 29, 2025. The event will focus on CLYM116, a preclinical-stage monoclonal antibody targeting APRIL, a key factor in pathogenic B cell activity related to autoimmune diseases. Developed for the treatment of IgA nephropathy (IgAN), CLYM116 employs a unique 'sweeper' mechanism of action intended to recycle the antibody and eliminate APRIL, potentially offering best-in-class efficacy with reduced dosing frequency. During the webcast, Climb Bio's management team and nephrologist Craig E. Gordon, MD, MS, will present an overview of IgAN, address unmet needs, and discuss the commercial opportunity for IgAN. Preclinical data comparing CLYM116 to a first-generation anti-APRIL monoclonal antibody, including head-to-head nonhuman primate results, will also be shared. Climb Bio plans to file an Investigational New Drug (IND) application or Clinical Trial Application $(CTA)$ for CLYM116 in the second half of 2025. The webcast will be accessible via the Climb Bio website, with a replay available for at least 30 days following the event.